We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NOVT:NASDAQNovanta Inc. Analysis

Data as of 2026-04-20 - not real-time

$129.86

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Novanta trades at $129.86, comfortably above its 20‑day SMA (~$121) and near its 50‑day SMA (~$129), with a bullish MACD histogram (+1.70) and an RSI of 59, indicating short‑term momentum without an overbought signal.
Nevertheless, a trailing P/E of 88 versus an industry average of 37 and a DCF fair value of $37 flag the stock as markedly overvalued, even as analysts have upgraded the rating to Outperform and project roughly 21% upside to the DCF target. The company delivers 8.5% revenue growth, solid cash generation, and no dividend, underscoring a growth‑oriented but pricey position.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price above short‑term moving averages
  • bullish MACD histogram
  • high valuation tempers upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • steady revenue and margin expansion
  • forward EPS growth and analyst upgrade to Outperform
  • potential ~21% upside to DCF target

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • ongoing demand in precision medical and automation markets
  • persistent valuation premium over fundamentals
  • strong cash position and low dividend reliance

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin5.49%
P/E Ratio88.3
ROE5.23%
ROA4.54%
Debt/Equity23.03
P/B Ratio3.5
Op. Cash Flow$64.1M
Free Cash Flow$64.3M
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI59.4
Support$112.51
Resistance$132.43
MA 20$121.23
MA 50$128.80
MA 200$121.27
MACDBullish
VolumeDecreasing
Fear & Greed Index87.59

Valuation

Fair Value$37.06
Target Price$157.00
Upside/Downside20.90%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.97
Volatility42.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.